Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

RCT (n=97) reports extended therapy with biannual rituximab infusions over 18 months was associated with lower incidence of relapse vs standard maintenance therapy (relapse-free survival 96% vs. 74% respectively, hazard ratio 7.5 [CI, 1.67 to 33.7], p= 0.008).


Annals of Internal Medicine